WO2002051389A3 - Aerogel powder comprising therapeutic agents - Google Patents

Aerogel powder comprising therapeutic agents Download PDF

Info

Publication number
WO2002051389A3
WO2002051389A3 PCT/US2001/049541 US0149541W WO02051389A3 WO 2002051389 A3 WO2002051389 A3 WO 2002051389A3 US 0149541 W US0149541 W US 0149541W WO 02051389 A3 WO02051389 A3 WO 02051389A3
Authority
WO
WIPO (PCT)
Prior art keywords
aerogel particles
therapeutic agents
aerogel powder
aerogel
aerogelized
Prior art date
Application number
PCT/US2001/049541
Other languages
French (fr)
Other versions
WO2002051389A2 (en
Inventor
Kang Lee
George Gould
Original Assignee
Aspen Aerogels Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aspen Aerogels Inc filed Critical Aspen Aerogels Inc
Priority to BR0115524-5A priority Critical patent/BR0115524A/en
Priority to KR10-2003-7006998A priority patent/KR20030077544A/en
Priority to IL15592001A priority patent/IL155920A0/en
Priority to CA002429773A priority patent/CA2429773A1/en
Priority to EP01992223A priority patent/EP1343479A2/en
Priority to JP2002552535A priority patent/JP2004516304A/en
Priority to MXPA03004340A priority patent/MXPA03004340A/en
Publication of WO2002051389A2 publication Critical patent/WO2002051389A2/en
Publication of WO2002051389A3 publication Critical patent/WO2002051389A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

Drugs in the form of very fine highly porous aerogel particles are delivered to a patient via inhalation. The aerogel particles are either an aerogelized form of a pharmaceutical or deposited upon aerogel particles produced from a non-inorganic oxide carrier matrix material, e.g. a sugar or carbohydrate. The aerogel particles are readily dissolvable by the pulmonary surfactant present in the lungs of a mammals.
PCT/US2001/049541 2000-12-22 2001-12-21 Aerogel powder comprising therapeutic agents WO2002051389A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
BR0115524-5A BR0115524A (en) 2000-12-22 2001-12-21 Dispersible dry powder for lung transfer and method of treating a disease state responsive to treatment by a therapeutic agent
KR10-2003-7006998A KR20030077544A (en) 2000-12-22 2001-12-21 Aerogel powder comprising therapeutic agents
IL15592001A IL155920A0 (en) 2000-12-22 2001-12-21 Aerogel powder comprising therapeutic agents
CA002429773A CA2429773A1 (en) 2000-12-22 2001-12-21 Aerogel powder comprising therapeutic agents
EP01992223A EP1343479A2 (en) 2000-12-22 2001-12-21 Aerogel powder therapeutic agents
JP2002552535A JP2004516304A (en) 2000-12-22 2001-12-21 Airgel powder containing therapeutic agent
MXPA03004340A MXPA03004340A (en) 2000-12-22 2001-12-21 Aerogel powder therapeutic agents.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25743600P 2000-12-22 2000-12-22
US60/257,436 2000-12-22

Publications (2)

Publication Number Publication Date
WO2002051389A2 WO2002051389A2 (en) 2002-07-04
WO2002051389A3 true WO2002051389A3 (en) 2003-01-16

Family

ID=22976300

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/049541 WO2002051389A2 (en) 2000-12-22 2001-12-21 Aerogel powder comprising therapeutic agents

Country Status (11)

Country Link
US (1) US6994842B2 (en)
EP (1) EP1343479A2 (en)
JP (1) JP2004516304A (en)
KR (1) KR20030077544A (en)
CN (1) CN1481236A (en)
BR (1) BR0115524A (en)
CA (1) CA2429773A1 (en)
IL (1) IL155920A0 (en)
MX (1) MXPA03004340A (en)
RU (1) RU2003122515A (en)
WO (1) WO2002051389A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10214226B4 (en) * 2001-10-11 2009-07-16 Arlt, Wolfgang Drug carrier, process for its preparation and use
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US6931888B2 (en) 2003-02-07 2005-08-23 Ferro Corporation Lyophilization method and apparatus for producing particles
US20040180915A1 (en) * 2003-03-14 2004-09-16 Xanodyne Pharmacal, Inc. Methadone-containing compositions for parenteral administration and method of use thereof
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
BRPI0508769A (en) 2004-03-30 2007-08-28 Euro Celtique Sa tamper-resistant dosage form comprising an adsorbent and an adverse agent
US7901606B2 (en) * 2004-07-12 2011-03-08 Ferro Corporation Production of porous materials by supercritical fluid processing
US20060127442A1 (en) * 2004-12-09 2006-06-15 Helmus Michael N Use of supercritical fluids to incorporate biologically active agents into nanoporous medical articles
EP2130877A1 (en) * 2008-06-06 2009-12-09 Fibac ApS Gel compositions
PT2209856T (en) * 2007-11-12 2019-10-25 Aerogel Aps Aerogel compositions
WO2010085641A1 (en) * 2009-01-22 2010-07-29 Noramco, Inc. Process for preparing particles of opioids and compositions produced thereby
US9125872B2 (en) * 2009-10-13 2015-09-08 Yosry A. Attia Polyethylene glycol aerogels for targeted delivery of pharmaceutical drubs
JP5883687B2 (en) * 2011-03-09 2016-03-15 第一三共ヘルスケア株式会社 Pharmaceutical composition containing a PDE5 inhibitor
CN102961342B (en) * 2012-12-13 2014-11-26 清华大学深圳研究生院 Nanoscale capecitabine and preparation method thereof
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
EP3607941A1 (en) 2013-04-30 2020-02-12 Otitopic Inc. Dry powder formulations and methods of use
JP6701086B2 (en) 2014-02-20 2020-05-27 オティトピック インコーポレイテッド Dry powder formulation for inhalation
US20160058045A1 (en) * 2014-08-26 2016-03-03 Pepsico, Inc. Method of Loading Flavor into an Aerogel and Flavor Impregnated Aerogel Based on Food Grade Materials
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
US10195147B1 (en) 2017-09-22 2019-02-05 Otitopic Inc. Dry powder compositions with magnesium stearate
EP3822395A1 (en) * 2019-11-13 2021-05-19 Fundación Imdea Materiales Nanowires network
WO2023170134A1 (en) 2022-03-08 2023-09-14 Aerogel-It Gmbh Process for producing porous materials

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001165A1 (en) * 1993-06-30 1995-01-12 Holmes, Michael, John Medical use of organic aerogels and biodegradable organic aerogels
DE19506141A1 (en) * 1995-02-22 1996-08-29 Hoechst Ag Use of aerogels in pharmacy, cosmetics and crop protection
US5958589A (en) * 1995-07-07 1999-09-28 The United States Of America As Represented By The Secretary Of Agriculture Starch-based microcellular foams
AU6554999A (en) * 1995-02-22 2000-03-02 Cabot Corporation Use of inorganic aerogels in pharmacy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5171293A (en) * 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
EP0868942A1 (en) * 1993-11-08 1998-10-07 The Gillette Company Method of forming particles using a supercritical fluid and aerogel particles formed thereby
ATE299892T1 (en) * 1994-05-18 2005-08-15 Nektar Therapeutics METHODS AND COMPOSITIONS FOR DRY POWDER MEDICATION FROM INTERFERONS
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6277489B1 (en) * 1998-12-04 2001-08-21 The Regents Of The University Of California Support for high performance affinity chromatography and other uses

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001165A1 (en) * 1993-06-30 1995-01-12 Holmes, Michael, John Medical use of organic aerogels and biodegradable organic aerogels
DE19506141A1 (en) * 1995-02-22 1996-08-29 Hoechst Ag Use of aerogels in pharmacy, cosmetics and crop protection
AU711078B2 (en) * 1995-02-22 1999-10-07 Cabot Corporation Use of aerogels in agriculture
AU6554999A (en) * 1995-02-22 2000-03-02 Cabot Corporation Use of inorganic aerogels in pharmacy
US5958589A (en) * 1995-07-07 1999-09-28 The United States Of America As Represented By The Secretary Of Agriculture Starch-based microcellular foams

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANDREWS M ET AL: "Transacetalation: a convenient, nonaqueous method for effecting the deprotection of isopropylidene and benzylidene derivatives of sugars", CARBOHYDRATE RESEARCH, vol. 229, no. 1, 1992, ISSN: 0008-6215, pages 141 - 147, XP002210074 *

Also Published As

Publication number Publication date
EP1343479A2 (en) 2003-09-17
WO2002051389A2 (en) 2002-07-04
JP2004516304A (en) 2004-06-03
CA2429773A1 (en) 2002-07-04
RU2003122515A (en) 2005-01-27
IL155920A0 (en) 2003-12-23
BR0115524A (en) 2003-09-16
CN1481236A (en) 2004-03-10
US20020094318A1 (en) 2002-07-18
US6994842B2 (en) 2006-02-07
KR20030077544A (en) 2003-10-01
MXPA03004340A (en) 2005-01-25

Similar Documents

Publication Publication Date Title
WO2002051389A3 (en) Aerogel powder comprising therapeutic agents
AU2002316820A1 (en) Powder inhaler formulations
WO2001005429A3 (en) Powder particles with smooth surface for use in inhalation therapy
CA2369722A1 (en) Powder inhaler for combined medicament
YU36302A (en) Novel tiotropium preparation -containing inhalation powder
AP1861A (en) Dry powder inhalation system for transpulmonary administration
CA2389349A1 (en) Aerosol composition comprising formoterol
CA2369726A1 (en) Powder inhaler for combined medicament
WO2002043702A3 (en) Pharmaceutical compositions for inhalation
CA2304975A1 (en) Stabilized preparations for use in metered dose inhalers
DK0633792T3 (en) Separator for powder inhalers
CA2406119A1 (en) Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets
AU2001293899A1 (en) Ihnalation particles incorporating a combination of two or more active ingredients
WO2001049274A3 (en) Methods for pulmonary delivery of interleukin-2
CA2461517A1 (en) Nicotine formulations comprising cocoa and use thereof
WO2001093837A3 (en) Protein powder for pulmonary delivery
TNSN05048A1 (en) Inhalation compositions with high drug ratios
WO2002015880A3 (en) Powdered mannitol and mannitol-containing compositions
AU3598299A (en) Improved compositions for inhalation
WO2002043693A3 (en) Pharmaceutical compositions for inhalation
CA2461757A1 (en) Nicotine formulations comprising chocolate and use thereof
EP1649886A3 (en) Unit dose capsules for a dry powder inhaler
GEP20074268B (en) Dry powder inhalation system for transpulmonary administration

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 155920

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002552535

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/004340

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 525946

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 647/KOLNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2429773

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001992223

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020037006998

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 018209742

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2002232689

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2001992223

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020037006998

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642